Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study – Eliem Therapeutics (NASDAQ:ELYM)
- 
- Eliem Therapeutics Inc ELYM announced interim results from its ongoing Stage 1 demo of ETX-155 for major depressive condition (MDD) and epilepsy.
- Adhering to reduced-than-anticipated drug exposure amounts in the three topics in a Period 1b photosensitive epilepsy (PSE) demo, Eliem initiated a Stage 1 demo in nutritious subjects to ensure the pharmacokinetic profile of ETX-155.
- ETX-155 demonstrates exposures in single dose 60-milligram cohorts of ongoing Section 1 pharmacokinetic demo reliable with prior trials.
- Also see: Eliem Therapeutics Shares Fall On Lessen Back Soreness Demo Setback.
- Eliem options to appraise a 75-milligram dose of ETX-155 in the repeat dose section of the ongoing Stage 1 pharmacokinetic demo in nutritious subjects.
- Ultimate results, such as the repeat dose cohort, are envisioned in Q4 of 2022.
- The company designs to start off the Section 2a MDD demo in Q1 of 2023, with the topline info predicted in mid-2024.
- The firm also stated it will not reinitiate the PSE evidence-of-principle trial but will proceed to go after the growth of ETX-155 in focal onset seizures.
- The business is progressing two preclinical candidates from the Kv7.2/3 channel opener plan for IND-enabling protection reports, predicted in Q1 of 2023, with Stage 1 research envisioned to start in 1H of 2024.
- The corporation has discontinued the preclinical advancement of a non-sedating anxiolytic for generalized panic problem because none of the compounds achieved the demanded profile.
- The business ended the September quarter with a money balance of $129.8 million, predicted to fund operations into 2025.
- Selling price Action: ELYM shares are trading lower by 1.97% at $2.98 on the last examine Wednesday.












© 2022 Benzinga.com. Benzinga does not provide investment guidance. All legal rights reserved.
